

Fellow Publications/Presentations January through December 2015

Publications

1. **Ai J**, Advani A. Current Status of Antibody Therapy in ALL. *Br J Haematol*. 2015 Feb;168(4):471-80
2. **Ai J**, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV. Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2. PMID: 25977195
3. **Emamekhoo H**, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. *Cell Cycle*. 2015 Oct 18;14(20):3213-4. doi: 10.1080/15384101.2015.1086201. No abstract available. PMID: 26313523
4. **Kruse M**, Peereboom D. *Cancer Neurology in Clinical Practice – Neurological Complications of Cancer and its Treatment*. Third Edition. Springer Science. 2015.
5. **Mi K**, Kalady MF, Quintini C, Khorana AA. Integrating systemic and surgical approaches to treating metastatic colorectal cancer. *Surg Oncol Clin N Am*. 2015 Jan;24(1):199-214. doi: 10.1016/j.soc.2014.09.006. Epub 2014 Oct 7. Review. PMID: 25444476
6. **Nazha A**, Khoury JD, Rampal R, Daver N. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical and Therapeutic Implications. *Oncologist*. 2015 Aug 24. pii: theoncologist.2015-0094. [Epub ahead of print].
7. **Nazha A**, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, Maciejewski JP. Genomic Patterns Associated with Hypoplastic Compared to Hyperplastic Myelodysplastic Syndromes. *Haematologica*. 2015 Aug 13. pii: haematol.2015.130112. [Epub ahead of print].
8. **Nazha A**, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? *Oncologist*. 2015 Jul 20. pii: theoncologist.2015-0067. [Epub ahead of print].
9. **Nazha A**, Seastone DJ, Keng M, Hobson S, Kalaycio M, Maciejewski JP, Sekeres MA. The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes. *Leukemia Lymphoma*. 2015 Jun 19:1-3. [Epub ahead of print].
10. Benton CB, **Nazha A**, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. *Crit Rev Oncol Hematol*. 2015 Mar 14. pii: S1040-8428(15)00049-9.
11. **Ornstein MC**, Mukherjee S, Keng M, Elson P, Tiu RV, Sauntharajah Y, Maggiotto A, Schaub M, Banks D, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid

leukemia induction therapy. Leuk Lymphoma. 2015 Sep;56(9):2536-42. doi: 10.3109/10428194.2014.1003557. Epub 2015 Feb 20. PMID: 25563427

12. **Ornstein MC**, Mukherjee S, Sekeres MA. More is Better: Combination Therapies in Myelodysplastic Syndromes. Best Pract Res Clin Haematol 2015;28(1):22-31.
13. **Ornstein MC**, Majhail NS, Gilligan TD. HCT in Testicular Cancer. In: BMT Handbook - Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation. Hoboken, NJ: John Wiley & Sons, Inc; *accepted for publication*
14. Bumma N, **Papadantonakis N**, Advani AS. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. Future Oncol. 2015;11(12):1729-39. doi: 10.2217/fon.15.84. PMID: 26075441
15. Nazha A, **Seastone D**, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, Carew J, Makishima H, Sekeres MA, Maciejewski JP. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015 Nov;100(11):e434-7. doi: 10.3324/haematol.2015.130112. Epub 2015 Aug 13. No abstract available. PMID: 26273060
16. Nazha A, **Seastone DP**, Keng M, Hobson S, Kalaycio M, Maciejewski JP, Sekeres MA. The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leuk Lymphoma. 2015 Sep 22:1-3. [Epub ahead of print] No abstract available. PMID: 25907427
17. **Seastone DJ**, Gerds AT. Darbepoetin alfa for anemia with myelodysplastic syndrome. Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12. Review. PMID: 25579702
18. Zhao X, Bodo J, **Sun D**, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015 Mar;168(5):765-8. doi: 10.1111/bjh.13149. Epub 2014 Oct 4. No abstract available. PMID: 25284608
19. **Thota S**, Sekeres MA. Combination Therapies for MDS and AML therapies: Does One Plus One Equal One? Leuk Lymphoma. 2015 Oct 1:1-9. [Epub ahead of print] No abstract available. PMID: 26428702
20. Bilori B, **Thota S**, et al. Tocaftinib as a novel salvage therapy for refractory T cell large granular lymphocytic leukemia. Leukemia (In press) PMID: 2644965
21. Molenaar RJ, **Thota S**, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015 Apr 3. PMID: 2583658
22. Mishra P, **Tiwari S**, Anand P. Recent Advances in Management of Anti-Coagulation in Atrial Fibrillation. 2015 J Heart Cardiol 1(3): 1-5. DOI: 10.15436/2378-6914.15.007.
23. **Zhao B**, Grivas P. Contemporary chemotherapy for urologic malignancies in geriatric patients. Clinics in Geriatric Medicine. Manuscript accepted for publication in 2015.

24. **Zhao B**, Yerram NK, Gao T, Dreicer R, Klein EA. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy. *Urologic Oncology*. 2015 Feb 6. PMID: 25665510 [Epub ahead of print].

Poster Presentations/Abstracts

1. **Agwa E**, Almeida F, Haddad A, Bastos B, Lee R, Jia X, Velcheti V, Ma P. Safety and clinical implications of repeat tumor biopsy (RTB) in patients with advanced lung cancer: A retrospective institutional study. 16th World conference on Lung cancer 09/2019
2. **Chi M**. An updated graded prognostic assessment for Her2 positive breast cancer patients with brain metastases. 2015 ASCO Annual Meeting. 06/2015
3. **Emamekhoo**, Chowdry R, Elson P, Ledet E, Martin A, Cotogno P, Beach J, Steinberger A, Allman K, Stolten M, Garcia J, Sartor O. Contemporary use of Radium-223 (Ra-223) in men with chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC): Feasibility and Safety. 2015 Genitourinary Cancers Symposium; Orlando, FL. 02/2015
4. **Fu S**, Rybicki L, Abounader D, Andresen S, Bolwell B, Dean R, Duong H, Gerds A, Hamilton B. Socioeconomic Status Influences Long-term Outcomes in 1-Year Survivors after Allogeneic Hematopoietic Cell Transplantation. Presented at 2015 Tandem Meeting; San Diego, CA. 02/2015
5. **Goodman, LM**, et al. Improving Guideline-Based Prophylactic Growth Factor (pGCSF) use with chemotherapy (CT) does not increase the risk of Febrile Neutropenia (FN) in Non-Small Cell Lung Cancer (NSCLC) patients (pts): a Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project. ASCO Annual Meeting. 06/2015
6. **Kruse M**, Santa-Maria CA, Raska P, Swoboda A, Jain S, Sohal D, Moore H, Budd GT, Abraham J, Montero AJ. Impact of genomic medicine on clinical decision making in patients with advanced breast cancer at two academic medical centers. 2015 San Antonio Breast Cancer Symposium, San Antonio, TX. 12/2015
7. **Menapace, LA**, Khorana AA, Smith B. Thrombocytosis in Malignancy and the Pro-Angiogenic State. Hemostasis and Thrombosis Research Society 2015 Scientific Symposium. Hilton New Orleans Riverside, New Orleans, LA. 04/2015
8. **Nazha A**, Narkhede M, Radivoyevitch T, et al. The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). American Society of Hematology Annual Meeting, Orlando, 12/2015. (Oral)
9. **Nazha A**, Zarzour A, Radivoyevitch T, et al. The Complexity of interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML). Submitted, American Society of Hematology Annual Meeting, Orlando, 12/2015. (Oral)

10. **Nazha A**, Przychodzen B, Carraway HE, et al. Network-Based Analysis of Exome Sequencing Mutations Identified Molecular Subtypes of Myelodysplastic Syndroms. American Society of Hematology Annual Meeting, Orlando, 12/2015. (**Oral**)
11. **Nazha A**, Radivoyevitch T, Thota S, et al. Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). Society of Hematologic Oncology Annual Meeting, Houston, 9/ 2015. (**Oral**)
12. **Nazha A**, Radivoyevitch T, Thota S, et al. Somatic Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). 13th International Symposium on Myelodysplastic Syndromes. Washington D.C., 2015. (**Oral**)
13. **Nazha A**, Meggendorfer M, Nadarajah N, et al. *TET 2* Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition. Presented, American Society of Hematology Annual Meeting, Orlando, 12/2015.
14. **Nazha A**, Komrokji RS, Garcia-Manero G, et al. A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. Presented, American Society of Hematology Annual Meeting, Orlando, 12/2015.
15. **Nazha A**, Narkhede M, Przychodzen B, et al. The Impact of Different *TP53* Mutations on Outcome in Patients with Myelodysplastic Syndromes (MDS). Society of Hematologic Oncology Annual Meeting, Houston, 9/2015.
16. **Nazha A**, Radivoyevitch T, Thota S, et al. Mutational Model to Predict Response to Hypomethylating Agents (HMAs) in Myelodysplastic Syndromes (MDS). Society of Hematologic Oncology Annual Meeting, Houston, 9/2015.
17. **Nazha A**, Przychodzen B, Narkhede M, et al. *APC* Mutations in Myeloid Malignancies: Incidence and Impact on Leukemogenesis. American Society of Clinical Oncology Annual Meeting, Chicago, 6/2015.
18. **Nazha A**, David Seastone, Hideki Makishima, et al. Obesity and genomic changes in patients with myelodysplastic syndromes. American Association of Cancer Research Annual Meeting, Philadelphia, 4/2015.
19. Zarzour A, **Nazha A**, Kalaycio M, et al. Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy. Presented, American Society of Hematology Annual Meeting, Orlando, 12/2015.
20. **Ornstein, MC**, Mukherjee S, Elson P, Pierce C, Zarzour A, Sauntharajah Y, Maggiotto A, Hobson S, Advani AS, Gerds AT, Carraway HE, Kalaycio ME, Maciejewski JP, Ellis S, Blackstone E, Sekeres MA. Risk of Bone Marrow Failure Conditions in Patients Undergoing Invasive Cardiac Interventions. Presented 13th International Symposium on Myelodysplastic Syndromes in Washington, DC, 05/2015.
21. **Ornstein, MC**, Knezevic V, Rini BI, Vaishampayan U. Association between Primary Tumor Protein Expression and Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Presented at ASCO GU conference in Orlando, FL. 02/2015

22. **Ornstein, MC**, Elson P, Garcia JA, Gilligan TD, Wood LS, Allman KD, Martin A, Rini BI. Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma – preliminary data. Presented at 2015 ASCO Annual Meeting in Chicago, IL. 06/2015.
23. **Ornstein MC**, L Wood, P Elson, K Allman, J Beach, A Martin, T Gilligan, J Garcia, B Rini. Clinical Effect of TKI-Dose Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma. 14th International Kidney Cancer Symposium, 11/2015 (**Oral**)
24. **Patel B**, Przychodzen B, Clemente M, et. al. Determinants of Phenotypic Commitment and Clonal Progression-Conclusions from the Study of Clonal Architecture in CMML. 57th ASH Annual Meeting and Exposition. December 2015, Orlando, FL. 12/2015
25. **Patel B**, Przychodzen B, Clemente M, et. al. Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. 57th ASH Annual Meeting and Exposition. December 2015, Orlando, FL. 12/2015 (**Oral**)
26. **Tiwari S**, Calhoun B, Abraham J, Budd GT, Moore HC, Grobmyer SR, Montero AJ. Efficacy and safety of neoadjuvant, docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in non-metastatic HER2+ breast cancer: The Cleveland Clinic Experience. ASCO 2015 Annual Meeting 06/2015
27. **Varella L**, Noble AR, Koyfman SA, Reddy CA, Greskovich J, Nwizu TI, Burkey B, Scharpf J, Khan M, Lorenz R, Lamarre E, Adelstein D. Retrospective analysis of benefit from concurrent chemoradiotherapy (CRT) in high-risk squamous cell carcinoma of the oral cavity (SCC-OC). 2015 ASCO Annual Meeting, Chicago, IL. 06/2015